Hardcast.& Waud (509597)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Exceptional recent momentum: sales growth of 110.79% and profit growth of 131.15%, with a PEG of just 0.13.
• Piotroski F-Score of 7/9 indicates reasonably solid fundamentals across profitability, leverage, and efficiency.
• Moderate valuation: P/E of 16.16 and P/B of 1.35, with book value of ₹653.52 providing some downside reference.
• Small market cap of ₹60 Cr leaves room for multi-year expansion if the specialty chemicals niche scales.

Concerns

• Very small absolute scale: latest quarter sales are only ₹3 Cr and net profit only ₹1 Cr; high growth rates are from a low base.
• Weak capital productivity: ROE of 6.60% and ROCE of 6.31% do not indicate a strong moat or pricing power.
• Zero dividend yield means minority shareholders get no income while waiting for uncertain growth.
• Promoter holding and debt/equity are undisclosed, making governance and financial risk impossible to assess.

AI Analysis

At first glance, Hardcast.& Waud looks like the kind of small specialty chemical idea that gets a growth investor's pulse quickening—but I try to keep my pulse steady. Sales are up 110.79% and profits up 131.15%, giving a PEG of 0.13. That is an eye-catching number. Yet when I look beneath the surface, I see a company with a market cap of just ₹60 Cr, quarterly sales of ₹3 Cr and net profit of ₹1 Cr. A 131% profit increase from a tiny base is progress, but it is not the same as a durable franchise. The returns on capital confirm my caution: ROE is only 6.60% and ROCE 6.31%. That tells me the business is not yet earning unusually high returns on retained capital, which is the real test of a moat. On the positive side, the Piotroski F-Score of 7/9 suggests the balance sheet and operations are not deteriorating, and the P/B of 1.35 gives me some margin of comfort against a book value of ₹653.52. At ₹882.50, the P/E of 16.16 is not outrageous if growth truly continues, but I do not pay 16 times earnings for a tiny company unless I can see the compounding machine working for a decade. I see no dividend, no promoter holding data, and no debt-to-equity information, which means I am flying partly blind. Graham would insist on margin of safety; Buffett would insist on evidence of pricing power. What I have here is a small, fast-growing specialty chemical company that deserves watching, but not yet my capital. The numbers are too small and the returns too modest for me to call it a true investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer